Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Merck & Co (NY: MRK)
74.66 USD  +0.57 (+0.77%)
Streaming Delayed Price  /  Updated: 2:03 PM EST, Nov 15, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 6,096,296
Open 73.50
Bid (Size) 74.65 (4)
Ask (Size) 74.67 (4)
Prev. Close 74.09
Today's Range 73.13 - 74.67
52wk Range 52.83 - 75.99
Shares Outstanding 2,690,303,898
Dividend Yield 2.56%
Performance
YTD
+32.80%
+32.80%
1 Month
+7.49%
+7.49%
3 Month
+10.82%
+10.82%
6 Month
+24.95%
+24.95%
1 Year
+35.77%
+35.77%
Top News
More News
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express
Merck’s KEYTRUDA Significantly Improved OS Compared to Chemotherapy in Patients with Advanced Esophageal Cancer Whose Tumors Express PD-L1 (CPS ?10) Read More
from Business Wire News Releases
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV?G-ZEBOV-GP) to U.S. Food and Drug Administration
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV?G-ZEBOV-GP) to U.S. Food and Drug Administration Read More
from Business Wire News Releases
More News
Read More
FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
from Business Wire News Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
from Business Wire News Releases
Novartis launches third-to-market Remicade copy in Germany
category companyNews
from Reuters: Company News
IVE, WMT, PFE, MRK: Large Inflows Detected at ETF
category ETFs
from ETF Channel
UPDATE 1-Merck drug Keytruda succeeds in late-stage esophageal cancer trial
category companyNews
from Reuters: Company News
Merck cancer drug Keytruda succeeds in late-stage trial
category companyNews
from Reuters: Company News
Can These 2 Battered Biotech Stocks Recover?
category ADRO , BMY , Market News , and 3 more.
from Motley Fool
UPDATE 1-Roche's Tecentriq wins fast FDA review in tough-to-treat breast cancer
category companyNews
from Reuters: Company News
October's biggest Losers And Most Surprising Winners
category MA , VZ , Finscreener , and 11 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.